GLP-1 Drugs Strain Hospital Budgets

The increasing demand for GLP-1 drugs such as Wegovy and Zepbound is placing immense financial pressure on healthcare systems across the United States. Dr. Joseph Cacchione, CEO of Jefferson, reported that his organization's spending on prescription drugs, driven by these weight loss medications, now surpasses its inpatient care expenses.

Jefferson's insurance arm experienced a significant loss of approximately $180 million in 2025, with a substantial portion attributed to GLP-1 coverage. This financial strain led to over 600 employee layoffs. To mitigate these costs, Jefferson's insurance plan implemented a policy requiring employees to engage in diet and lifestyle programs before approving GLP-1s for weight loss, a measure that has already yielded $20 million in savings.

Nationally, employers and insurers are grappling with the escalating costs. A KFF survey indicated that by 2025, roughly one in five large employers covered GLP-1s for weight loss, with approximately one-third of those requiring prior lifestyle interventions. This marks a considerable increase from the previous year, highlighting a growing trend of employers tightening access to these medications due to unexpected spending shocks.

While pharmaceutical companies are exploring cost-reduction strategies, such as Novo Nordisk's plan to halve Wegovy's list price by 2027, Cacchione believes further price reductions are necessary. The debate continues regarding who should bear the cost of these effective but expensive treatments, especially considering their long-term health benefits versus immediate budgetary impacts on health systems.